AINOS INC Stock Price, News & Analysis

Ainos (NASDAQ:AIMD) announced a 1-for-5 stock consolidation effective June 30, 2025, aimed at attracting institutional investors and maintaining Nasdaq listing compliance. The consolidation will automatically convert every 5 shares into 1 share, with fractional shares paid in cash.

The company is entering a commercial execution phase in 2H 2025, focusing on two main verticals: AI Nose, an AI-powered scent digitization platform entering scaled field testing across senior care, robotics, and semiconductor manufacturing, and VELDONA®, a low-dose oral interferon in clinical development for both human and veterinary applications including feline chronic gingivostomatitis, Sjögren's syndrome, and HIV-related oral warts.

Ainos (NASDAQ:AIMD) has formed a strategic partnership with Kenmec Mechanical Engineering to integrate AI-powered scent intelligence into smart factories across Asia. The partnership enables Kenmec to deploy AI Nose and smell language model (SLM) technologies in automation solutions, with Kentec Inc. appointed as a manufacturing partner.

The collaboration follows Ainos' successful implementations in Japan's eldercare sector and semiconductor smart factories. The technology digitizes scent into Smell ID, enabling machines to interpret and act on scent signals. The digital scent technology market is projected to grow from $1.09B (2023) to $2.56B by 2032, while the electronic nose market is expected to reach $132.6B by 2034.

Water Tower Research has published a report highlighting Ainos' (NASDAQ:AIMD) significant progress in AI-powered scent digitization and healthcare solutions. The company's AI Nose technology achieved 85% accuracy in hygiene monitoring and generated first-time revenues in Q1 2025 from elderly care programs in Japan. Ainos completed integration with ugo's service robots and plans field testing in public infrastructure settings during 2H25. The company expanded its semiconductor partnership with ASE, identifying over 30 use cases for AI Nose. In healthcare, Ainos secured Taiwan regulatory approval for Veldona® human trials targeting HIV-related warts and Sjogren's syndrome, with studies expected to complete by 2H26 and 1H27. Additionally, preliminary results from veterinary studies showed 10-44% symptom improvements in Feline Chronic Gingivostomatitis with reduced steroid usage.

Ainos (NASDAQ:AIMD) reported significant progress in H1 2025, marking a strategic transition from R&D to commercial execution. The company achieved 412% year-over-year Q1 revenue growth, primarily driven by its AI Nose technology deployment in Japan's senior care sector. The AI Nose platform, which digitizes scent through MEMS gas sensors and AI algorithms, has expanded into multiple sectors including healthcare, robotics, and semiconductors. Key developments include partnership with ugo Inc. for the world's first robotic smell integration, collaboration with ASE for smart factory operations, and improved accuracy rates reaching 85-90% across applications. Additionally, Ainos' VELDONA oral interferon received approval for human trials in Taiwan targeting HIV-related oral warts and primary Sjögren's syndrome, while showing promising results in veterinary trials for feline chronic gingivostomatitis.

Water Tower Research has published a report highlighting Ainos' (NASDAQ: AIMD) significant breakthrough in AI Nose technology for elderly care monitoring. The AI-powered scent digitization system has achieved 85% accuracy in excretion odor detection, with 92% sensitivity, based on 254 subject events and 2,119 sample entries from Japan and Taiwan. The technology addresses critical caregiving challenges in aging Asian populations, with Japan facing a projected shortfall of 570,000 caregivers by 2040. Ainos plans commercial deployment in long-term care facilities by 2026, following pilot testing in late 2025. The company is positioning itself within the $29.8 billion global electronic nose market, leveraging favorable healthcare policies in Japan and Taiwan to accelerate adoption.

Ainos (NASDAQ: AIMD) announced that its AI Nose platform has achieved an 85% accuracy rate in detecting excretion odors, up from 80%, based on data from 254 participants in Japan and Taiwan. The AI Nose technology digitizes scent into Smell IDs using MEMS gas sensors and proprietary AI models built on 13 years of scent data. The company plans commercial rollout starting with pilot deployments in Japan in H2 2025, followed by expansion across Asia-Pacific in 2026. Ainos is targeting the long-term care sector, particularly in Japan and Taiwan where aging populations present significant challenges. The global electronic nose market is projected to grow from $29.8B in 2025 to $76.5B by 2032, at a 14.4% CAGR. The company is also partnering with a leading Japanese service robotics company to integrate AI Nose into autonomous robots.

Ainos (NASDAQ:AIMD) is showcasing its breakthrough AI Nose technology at COMPUTEX 2025 in partnership with ugo, Japan's leading service robotics company. The AI Nose platform represents a significant advancement in robotic olfaction, utilizing MEMS gas sensor arrays and machine learning to digitize scents into Smell IDs. The technology achieves 99% accuracy in model development, with 90% accuracy in healthcare applications and 80% in semiconductor environments. The electronic nose market is projected to reach $76.5 billion by 2032. The demonstration at COMPUTEX 2025, themed "AI Next," will showcase AI-powered scent digitization applications in smart infrastructure, elder care, and industrial safety at Booth InnoVEX S0324 at Taipei Nangang Exhibition Center.

Ainos (NASDAQ: AIMD) has reported promising interim results from its veterinary clinical trial of VELDONA, a low-dose interferon therapy for Feline Chronic Gingivostomatitis (FCGS). The trial, involving 30 cats, shows significant improvements in treating chronic inflammation. Key findings from the first three completed cases include inflammation score reductions ranging from 10.5% to 44.4%, with successful reduction or elimination of steroid dependency. The therapy demonstrated strong tolerability with no significant side effects. This breakthrough positions Ainos to tap into the global pet dental market, projected to reach $13 billion by 2030. The results suggest VELDONA could revolutionize companion animal immunotherapy by offering a steroid-free treatment option for chronic inflammatory conditions.

Ainos (NASDAQ:AIMD) has achieved significant commercial progress with its AI-powered scent digitization platform, AI Nose, as highlighted in a Water Tower Research report. The company reported a 412% year-over-year revenue growth, primarily driven by AI Nose sales in Japan's elderly care market through its partnership with Nisshinbo Micro Devices Inc.

The company reached a key milestone with over 80% accuracy in detecting bowel movements in elderly patients through its AI Nose technology. This achievement is particularly significant for Japan's aging healthcare market, which faces a projected shortage of 570,000 caregivers by 2040.

Ainos has expanded AI Nose applications beyond healthcare into robotics and industrial sectors. Notable developments include successful integration with ugo's service robots and a partnership with a major semiconductor company for smart factory applications across 46 facilities.